Elasmogen is a privately held biopharmaceutical company located in the thriving biologics cluster in Aberdeen, Scotland. The Company is rapidly progressing a pipeline of next-generation soloMER products for the treatment solid-tumour cancers, systemic inflammatory diseases and inflammatory conditions of the gut.

Whilst they share some similarities in terms of their structure and properties with antibodies soloMERs™ are smaller (11 kDa) and more stable proteins, have squeezed a fourth binding loop into their single domain format and crucially are derived evolutionarily from a non-antibody lineage, placing them outside the complex/competitive antibody patent landscape.